Menopause Treatment Market 2022
Menopause causes uncomfortable symptoms, such as hot flashes, vaginal dryness, and weight gain and menopause treatments such as hormonal and non-hormonal treatments help to relieve these symptoms. Over the years, major market players in the menopause treatment are focusing on various growth strategies such as product launches, product advancements and expansions to cater to the growing needs for patients seeking treatment for menopause symptoms.
Global Menopause Treatment Market is expected to have a market value of USD 15,456.3 Million by 2027.
For instance, in April 2019, Otsuka Pharmaceutical launched EQUELLE, a non-prescription, non-hormonal supplement to alleviate the frequency of hot flashes and muscle aches associated with menopause in the US. Such strategies push the demand for branded as well as generic menopausal drugs, thus promising huge growth for the industry.
Access Full Report Details and Order this Premium Report @ https://www.marketresearchfuture.com/reports/menopause-treatment-market-4579
Major Key Players:
MRFR recognizes the following companies as the Key Players in the Global Menopause Treatment Market— Novo Nordisk A/S (Denmark), Pfizer Inc. (US), Allergan (Ireland), Eli Lily and Company (US), Emcure Pharmaceuticals Ltd (India), Novartis AG (Switzerland), Cipla Inc. (India), Teva Pharmaceuticals (Israel), Merck & Co., Inc. (US), Abbott Laboratories (US).
The global menopause treatment market is segmented based on treatment and distribution channel.
The global menopause treatment market based on the treatment has been segmented into hormonal treatment and non-hormonal treatment. The hormonal treatment segment is further segmented into estrogen, progesterone, and combination. The non-hormonal treatment is further segmented into anti-depressants and others.
Based on distribution channel, the menopause treatment market is segmented into hospital pharmacies, retail pharmacies, and online stores.
The global menopause treatment market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The Americas led the market and accounted for the largest share in 2019 owing to the increasing product approvals and high uptake of new technology. For instance, in July 2017, AMAG Pharmaceuticals, Inc. (US) launched Intrarosa (prasterone) for the treatment of moderate to severe dyspareunia a symptom of vulvar and vaginal atrophy (VVA), due to menopause. Thus, such strategies employed by major players aid in the increased growth rate for the Americas menopause treatment industry.
The European menopause treatment market has been further segmented into Western Europe and Eastern Europe. The Western Europe menopause treatment market has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. Europe follows the Americas in the global menopause treatment market. The increasing inclination of companies towards female technology (femtech) is boosting the growth of the menopause treatment market in European countries. Many digital health start-ups have identified this opportunity and are offering B2C digital health tools, such as mobile apps, to guide menopausal women through this phase with lifestyle intervention tips and online telehealth consultations. As a result, the region is expected to show significant growth in the menopause treatment market.
The menopause treatment market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the rest of Asia-Pacific. Asia-Pacific is expected to register the highest growth rate over the forecast period from 2020 to 2027. This is owing to the growing penetration of the women’s health sector, increasing awareness about the betterment of the women’s health, and the growing number of educational campaigns related to the benefits of hormone replacement therapy in China, Japan, India, and Australia.
The Middle East & Africa menopause treatment market is segmented Saudi Arabia, the United Arab Emirates (UAE), Oman, Kuwait, Qatar, and the rest of the Middle East & Africa. The negative connotation of menopause has resulted in a negative attitude towards menopause in premenopausal women. However, with the increasing awareness created by private companies, the scenario is expected to change in the next ten years.
Browse Related Reports:
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312